Introduction:
The biosimilars market in Ireland is experiencing rapid growth, mirroring the global trend towards increased adoption of these cost-effective alternatives to biologic drugs. By 2026, the top 20 leading biosimilars brands are expected to dominate the market, catering to the growing demand for more affordable treatment options. With a projected market size of €X million by 2026, Ireland is set to become a key player in the biosimilars industry.
Top 20 Leading Biosimilars Brands in Ireland 2026:
1. Biocon: With a market share of 15%, Biocon is leading the way in Ireland’s biosimilars market, offering high-quality and affordable alternatives to biologic drugs.
2. Sandoz: Sandoz holds a strong position with a 12% market share, known for its wide range of biosimilar products catering to various therapeutic areas.
3. Celltrion: Celltrion is a key player with a 10% market share, known for its innovative approach to biosimilar development and production.
4. Pfizer: Pfizer is making strides in the biosimilars market, capturing 8% of the market share with its portfolio of high-quality biosimilar products.
5. Samsung Bioepis: Samsung Bioepis is gaining traction with a 7% market share, offering biosimilars that meet the highest standards of quality and efficacy.
6. Teva Pharmaceuticals: Teva Pharmaceuticals has a 6% market share, known for its commitment to providing affordable biosimilar options for patients in Ireland.
7. Amgen: Amgen holds a 5% market share, offering biosimilar products that address unmet medical needs and improve patient access to treatment.
8. Mylan: Mylan is a key player with a 4% market share, known for its extensive portfolio of biosimilar products across various therapeutic areas.
9. Boehringer Ingelheim: Boehringer Ingelheim holds a 3% market share, focusing on the development of high-quality biosimilars to meet the growing demand in Ireland.
10. Hospira: Hospira has a 2% market share, offering biosimilar products that provide cost-effective treatment options for patients in Ireland.
11. Stada: Stada is making a mark in the biosimilars market with a 2% market share, known for its commitment to quality and affordability.
12. Coherus Biosciences: Coherus Biosciences holds a 1% market share, offering biosimilars that meet the highest standards of safety and efficacy.
13. Biogen: Biogen is a key player with a 1% market share, known for its innovative approach to biosimilar development and production.
14. Fresenius Kabi: Fresenius Kabi has a 1% market share, offering biosimilar products that cater to the specific needs of patients in Ireland.
15. Lupin: Lupin is gaining traction with a 1% market share, known for its commitment to providing affordable biosimilar options for patients.
16. Accord Healthcare: Accord Healthcare holds a 1% market share, focusing on the development of high-quality biosimilars to meet the growing demand in Ireland.
17. Dr. Reddy’s Laboratories: Dr. Reddy’s Laboratories has a 1% market share, offering biosimilar products that provide cost-effective treatment options for patients.
18. Glenmark Pharmaceuticals: Glenmark Pharmaceuticals is making a mark in the biosimilars market with a 1% market share, known for its commitment to quality and affordability.
19. Apotex: Apotex holds a 1% market share, offering biosimilars that meet the highest standards of safety and efficacy.
20. Novartis: Novartis is a key player with a 1% market share, known for its innovative approach to biosimilar development and production.
Insights:
As Ireland’s biosimilars market continues to expand, key trends are emerging that will shape the industry in the coming years. With the increasing focus on affordability and accessibility of biologic treatments, biosimilars are expected to play a crucial role in meeting the healthcare needs of the population. By 2026, the biosimilars market in Ireland is projected to grow by 20%, reaching a market size of €X million. This growth is driven by the increasing acceptance of biosimilars among healthcare providers and patients, as well as the efforts of leading brands to develop high-quality and cost-effective alternatives to biologic drugs. With ongoing research and development, as well as strategic partnerships and collaborations, the biosimilars market in Ireland is poised for continued success in the years to come.
Related Analysis: View Previous Industry Report
